Alniditan HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525332

CAS#: 155428-00-5 (HCl)

Description: Alniditan is a 5-HT1B/D receptor agonist that may be used in the treatment of migraines. Alniditan selectively constricts porcine carotid arteriovenous anastomoses via 5-HT1B/1D receptors. alniditan is a potent agonist at h5-HT1D alpha and h5-HT1D beta receptors; its properties probably underlie its cranial vasoconstrictive and antimigraine properties.

Chemical Structure

img
Alniditan HCl
CAS# 155428-00-5 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 525332
Name: Alniditan HCl
CAS#: 155428-00-5 (HCl)
Chemical Formula: C17H28Cl2N4O
Exact Mass: 374.16
Molecular Weight: 375.338
Elemental Analysis: C, 54.40; H, 7.52; Cl, 18.89; N, 14.93; O, 4.26

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 155428-00-5 (HCl)   152317-89-0 (free base)    

Synonym: Alniditan dihydrochloride; Alniditan HCl; Alniditan; R 91274; R91274; R-91274; R091274, R-091274, R 091274, JNJ 16384810-AAC; JNJ 16384810; JNJ-16384810; JNJ16384810;

IUPAC/Chemical Name: N-[[(2R)-3,4-Dihydro-2H-chromen-2-yl]methyl]-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine dihydrochloride

InChi Key: GDNITZYKOOTAFK-QCUBGVIVSA-N

InChi Code: InChI=1S/C17H26N4O.2ClH/c1-2-6-16-14(5-1)7-8-15(22-16)13-18-9-3-10-19-17-20-11-4-12-21-17;;/h1-2,5-6,15,18H,3-4,7-13H2,(H2,19,20,21);2*1H/t15-;;/m1../s1

SMILES Code: [H]Cl.[H]Cl.C1(NCCCNC[C@H]2CCC3=C(O2)C=CC=C3)=NCCCN1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 375.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Do TP, Guo S, Ashina M. Correction to: Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019 May 17;20(1):55. doi: 10.1186/s10194-019-1013-0. Erratum for: J Headache Pain. 2019 Apr 17;20(1):37. PMID: 31100999; PMCID: PMC6734468.


2: Rapoport AM. The therapeutic future in headache. Neurol Sci. 2012 May;33 Suppl 1:S119-25. doi: 10.1007/s10072-012-1056-3. PMID: 22644186.


3: Nugroho AK, Della-Pasqua O, Danhof M, Bouwstra JA. Compartmental modeling of transdermal iontophoretic transport II: in vivo model derivation and application. Pharm Res. 2005 Mar;22(3):335-46. doi: 10.1007/s11095-004-1870-2. PMID: 15835738.


4: Janssen P, Tack J, Sifrim D, Meulemans AL, Lefebvre RA. Influence of 5-HT1 receptor agonists on feline stomach relaxation. Eur J Pharmacol. 2004 May 25;492(2-3):259-67. doi: 10.1016/j.ejphar.2004.03.054. PMID: 15178373.


5: Goadsby PJ, Classey JD. Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience. 2003;122(2):491-8. doi: 10.1016/s0306-4522(03)00570-0. PMID: 14614913.


6: Newman-Tancredi A, Cussac D, Marini L, Touzard M, Millan MJ. h5-HT(1B) receptor-mediated constitutive Galphai3-protein activation in stably transfected Chinese hamster ovary cells: an antibody capture assay reveals protean efficacy of 5-HT. Br J Pharmacol. 2003 Mar;138(6):1077-84. doi: 10.1038/sj.bjp.0705140. PMID: 12684263; PMCID: PMC1573751.


7: Bhalla P, Sharma HS, Wurch T, Pauwels PJ, Saxena PR. Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht(1F) receptor. Eur J Pharmacol. 2002 Feb 1;436(1-2):23-33. doi: 10.1016/s0014-2999(01)01605-3. PMID: 11834243.


8: Diener HC, Tfelt-Hansen P, de Beukelaar F, Ferrari MD, Olesen J, Dahlöf C, Mathew N; Study Group. The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2001 Jul;21(6):672-9. doi: 10.1046/j.0333-1024.2001.00222.x. PMID: 11531899.


9: Diener HC, Louis P, Schellens R, De Beukelaar F; Study Group. Treatment of migraine attacks with intranasal alniditan: an open study. Cephalalgia. 2001 Mar;21(2):140-4. doi: 10.1046/j.1468-2982.2001.00182.x. PMID: 11422097.


10: Boers PM, Donaldson C, Zagami AS, Lambert GA. 5-HT(1A) and 5-HT(1B/1D) receptors are involved in the modulation of the trigeminovascular system of the cat: a microiontophoretic study. Neuropharmacology. 2000 Jul 24;39(10):1833-47. doi: 10.1016/s0028-3908(99)00241-5. PMID: 10884564.


11: Bouchelet I, Case B, Olivier A, Hamel E. No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J Pharmacol. 2000 Feb;129(3):501-8. doi: 10.1038/sj.bjp.0703081. PMID: 10711348; PMCID: PMC1571865.


12: Limmroth V, Bischoff A, Fetscher C, Wermelskirchen D, Diener H, Michel MC. Effects of alniditan on neurogenic oedema in the rat dura mater and on contraction of rat basilar artery. Eur J Pharmacol. 1999 Oct 8;382(2):103-9. doi: 10.1016/s0014-2999(99)00602-0. PMID: 10528144.


13: Bonaventure P, Umans L, Bakker MH, Cras P, Langlois X, Luyten WH, Megens AA, Serneels L, Van Leuven F, Leysen JE. Humanization of mouse 5-hydroxytryptamine1B receptor gene by homologous recombination: in vitro and in vivo characterization. Mol Pharmacol. 1999 Jul;56(1):54-67. doi: 10.1124/mol.56.1.54. PMID: 10385684.


14: Roon KI, Soons PA, Uitendaal MP, de Beukelaar F, Ferrari MD. Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks. Br J Clin Pharmacol. 1999 Mar;47(3):285-90. doi: 10.1046/j.1365-2125.1999.00894.x. PMID: 10215753; PMCID: PMC2014228.


15: Jadoul A, Lecouturier N, Mesens J, Caers W, Préat V. Transdermal alniditan delivery by skin electroporation. J Control Release. 1998 Aug 14;54(3):265-72. doi: 10.1016/s0168-3659(97)00195-8. PMID: 9766246.


16: De Vries P, Willems EW, Heiligers JP, Villalón CM, Saxena PR. The antimigraine agent alniditan selectively constricts porcine carotid arteriovenous anastomoses via 5-HT1B/1D receptors. Eur J Pharmacol. 1998 Jun 19;351(2):193-201. doi: 10.1016/s0014-2999(98)00301-x. PMID: 9687003.


17: Lesage AS, Wouters R, Van Gompel P, Heylen L, Vanhoenacker P, Haegeman G, Luyten WH, Leysen JE. Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65. doi: 10.1038/sj.bjp.0701766. PMID: 9605573; PMCID: PMC1565323.


18: Bonaventure P, Voorn P, Luyten WH, Jurzak M, Schotte A, Leysen JE. Detailed mapping of serotonin 5-HT1B and 5-HT1D receptor messenger RNA and ligand binding sites in guinea-pig brain and trigeminal ganglion: clues for function. Neuroscience. 1998 Jan;82(2):469-84. doi: 10.1016/s0306-4522(97)00302-3. PMID: 9466454.


19: Schoenen J. Acute migraine therapy: the newer drugs. Curr Opin Neurol. 1997 Jun;10(3):237-43. doi: 10.1097/00019052-199706000-00012. Erratum in: Curr Opin Neurol 1997 Oct;10(5):following 136. PMID: 9229132.


20: Newman-Tancredi A, Conte C, Chaput C, Verrièle L, Audinot-Bouchez V, Lochon S, Lavielle G, Millan MJ. Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):682-8. doi: 10.1007/pl00005000. PMID: 9205951.